OMNICARE INC
S-3/A, 1997-11-21
DRUG STORES AND PROPRIETARY STORES
Previous: MEDICAL GRAPHICS CORP /MN/, SC 13D/A, 1997-11-21
Next: IBM CREDIT CORP, 424B3, 1997-11-21



<PAGE>   1
                                                   REGISTRATION NO. 333-36665


                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                            ---------------------
                               AMENDMENT NO 1.
                                      TO
                                   FORM S-3
                            REGISTRATION STATEMENT
                                    UNDER
                          THE SECURITIES ACT OF 1933
                                      
                             --------------------

                                 OMNICARE, INC.
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

<TABLE>
<CAPTION>
                           DELAWARE                                                         31-1001351
<S>                                                                              <C>
(State or other jurisdiction of incorporation or organization)                   (I.R.S. Employer Identification No.)
</TABLE>

               50 EAST RIVERCENTER BLVD. - SUITE 1530, COVINGTON,
                         KENTUCKY 41011; (606) 655-1180
    (Address, including zip code, and telephone number, including area code,
                  of registrant's principal executive offices)

                                CHERYL D. HODGES
                         C/O OMNICARE MANAGEMENT COMPANY
                     2800 CHEMED CENTER, 255 E. FIFTH STREET
                     CINCINNATI, OHIO 45202; (513) 762-6666
            (Name, address, including zip code, and telephone number,
                   including area code, of agent for service)

                                   Copies to:

                                MORTON A. PIERCE
                                DEWEY BALLANTINE LLP
                           1301 AVENUE OF THE AMERICAS
                            NEW YORK, NEW YORK 10019

         APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: As
soon as practicable after the Registration Statement becomes effective.

         If the only securities being registered on this Form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box. [ ]

         If any of the securities being registered on this Form are to be
offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, other than securities offered only in connection with
dividend or interest reinvestment, please check the following box: [X]

         If this Form is filed to register additional securities of an offering
pursuant to Rule 462(b) under the Securities Act of 1933, please check the
following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering. [ ]

         If this Form is a post-effective amendment filed pursuant to Rule
462(c) under the Securities Act of 1933, check the following box and list the
Securities Act registration statement number of the earlier effective
registration statement for the same offering. [ ]

         If delivery of the prospectus is expected to be made pursuant to Rule
434, please check the following box. [ ]


                         CALCULATION OF REGISTRATION FEE
<TABLE>
<CAPTION>
===============================================================================================================================

 TITLE OF EACH CLASS OF SECURITIES       AMOUNT TO BE      PROPOSED MAXIMUM OFFERING     PROPOSED MAXIMUM        AMOUNT OF
          TO BE REGISTERED                REGISTERED           PRICE PER SHARE(1)       AGGREGATE OFFERING    REGISTRATION FEE
                                                                                            PRICE (1)
===============================================================================================================================
<S>                                   <C>                  <C>                         <C>                   <C>
Common Stock.....................     676,056              $29.50                      $19,943,652           $6,044   
===============================================================================================================================
</TABLE>

(1)      Estimated solely for the purpose of calculating the registration fee
         pursuant to Rule 457(c), based upon the average of the high and low
         reported prices of the Common Stock on the New York Stock Exchange
         Composite Tape on September 22, 1997.
                                                       

         The Registrant hereby amends this Registration Statement on such date
or dates as may be necessary to delay its effective date until the Registrant
shall file a further amendment which specifically states that this Registration
Statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933 or until the Registration Statement shall become
effective on such date as the Commission, acting pursuant to said Section 8(a),
may determine.
<PAGE>   2
                                 OMNICARE, INC.

                                  COMMON STOCK

         This Prospectus covers the offering for resale of 676,056 shares (the
"Shares" ) of Common Stock, par value $1.00 per share, of Omnicare, Inc.
("Omnicare" or the "Company") by the Selling Stockholders named herein under
"Selling Stockholders," who acquired the Shares in connection with acquisitions
by Omnicare and its subsidiaries of certain assets of (i) Brookside Park
Pharmacy, Inc., (ii) Brookside Park Pharmacy of Texas, L.L.C. and (iii)
Brookside Park Pharmacy of Illinois, L.L.C. Omnicare will not receive any
proceeds from the sale of the Shares covered by this Prospectus.

         The Common Stock is listed on the New York Stock Exchange under the
symbol OCR.

         The Shares covered by this Prospectus may be offered for sale from time
to time on the New York Stock Exchange or otherwise, at prices then obtainable.
The Company has agreed to indemnify the Selling Stockholders against certain
liabilities, including liabilities under the Securities Act of 1933 (the "Act").
See "Plan of Distribution."

         Certain persons who sell the Shares covered by this Prospectus, and any
broker or dealer to or through whom any such person shall sell such securities,
may be deemed to be underwriters within the meaning of the Act with respect to
the sale of such securities.

                           --------------------------

             THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED
                BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY
                     STATE SECURITIES COMMISSION NOR HAS THE
                      SECURITIES AND EXCHANGE COMMISSION OR
                   ANY STATE SECURITIES COMMISSION PASSED UPON
                  THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS.
                     ANY REPRESENTATION TO THE CONTRARY IS A
                                CRIMINAL OFFENSE.

                           --------------------------


               The date of this Prospectus is November 24, 1997

                                       2
<PAGE>   3
         NO DEALER, SALESMAN OR ANY OTHER PERSON HAS BEEN AUTHORIZED BY THE
COMPANY TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATIONS OTHER THAN AS
CONTAINED IN THIS PROSPECTUS IN CONNECTION WITH THE OFFERING DESCRIBED HEREIN.
THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER OR A SOLICITATION WITHIN ANY STATE
TO ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION.

                              AVAILABLE INFORMATION

         Omnicare is subject to the information requirements of the Securities
Exchange Act of 1934 (the "Exchange Act"), and in accordance therewith files
reports, proxy statements and other information with the Securities and Exchange
Commission (the "Commission"). These reports, proxy statements and other
information may be inspected and copied at the public reference facilities
maintained by the Commission at its principal offices at Judiciary Plaza, 450
Fifth Street, N.W., Washington, D.C. 20549, and at the Commission's regional
offices located at Citicorp Center, 500 West Madison Street, Suite 1400,
Chicago, Illinois 60661, and 7 World Trade Center, Suite 1300, New York, New
York 10048. Copies of such materials can also be obtained from the Public
Reference Section of the Commission at prescribed rates at the principal offices
of the Commission at Judiciary Plaza, 450 Fifth Street, N.W., Washington, D.C.
20549. The Commission maintains an Internet web site that contains reports,
proxy and information statements and other information regarding issuers that
file electronically with the Commission. The address of that site is
http://www.sec.gov. The Company's Common Stock is listed on the New York Stock
Exchange (Symbol: OCR), and reports and information concerning the Company can
be inspected at such exchange, 20 Broad Street, New York, New York 10005.

         The Company has filed with the Commission a Registration Statement on
Form S-3 under the Act with respect to the Common Stock offered hereby
(including all amendments and supplements thereto, the "Registration
Statement"). This Prospectus, which forms a part of the Registration Statement,
does not contain all the information set forth in the Registration Statement and
the exhibits filed therewith, certain parts of which have been omitted in
accordance with the rules and regulations of the Commission. Statements
contained herein concerning the provisions of such documents are not necessarily
complete and, in each instance, reference is made to the copy of such document
filed as an exhibit to the Registration Statement or otherwise filed with the
Commission. Each such statement is qualified in its entirety by such reference.
The Registration Statement and the exhibits thereto can be inspected and copied
at the public reference facilities and regional offices referred to above.

                                       3
<PAGE>   4
                 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

         The Company hereby incorporates in this Prospectus by reference the
following documents heretofore filed with the Commission pursuant to the
Exchange Act: (i) the Company's Annual Report on Form 10-K for the year ended
December 31, 1996 (as amended on Form 10-K/A filed August 6, 1997); (ii) the
Company's Quarterly Reports on Form 10-Q for the quarters ended March 30, 1997
(as amended on Form 10-Q/A filed August 6, 1997), June 30, 1997 (filed
August  13, 1997), and September 30, 1997 (filed November 14, 1997); (iii) the
Company's Current Reports on Form 8-K dated January 31, 1997 (filed February
21, 1997), dated February 6, 1997 (filed February 6, 1997), dated May 31, 1997
(filed June 19, 1997), dated August 6, 1997 (filed August 6, 1997), dated
August 8, 1997 (filed August 8, 1997) and dated September 12, 1997 (filed
September 19, 1997, as amended on Form 8-K/A filed September 29, 1997); and
(iv) the description of the Company's Common Stock in the Company's
registration statement on Form  8-A under the Exchange Act (File No. 1-08269)
filed September 14, 1993, including all amendments and reports filed for the
purpose of updating such description.

         All documents filed by the Company pursuant to Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act subsequent to the date of this Prospectus and
prior to termination of this offering shall be deemed to be incorporated in this
Prospectus reference and to be a part hereof from the respective dates of the
filing of such documents. Any statement contained herein or in a document
incorporated or deemed to be incorporated by reference herein shall be deemed to
be modified or superseded for purposes of this Prospectus to the extent that a
statement contained herein or in any subsequently filed document which also is,
or is deemed to be, incorporated by reference herein, modifies or supersedes
such statement. Any statement so modified or superseded shall not be deemed,
except as so modified or superseded, to constitute part of this Prospectus.

         The Company hereby undertakes to provide without charge to each person
to whom a copy of this Prospectus has been delivered, upon the written or oral
request of any such person, a copy of any and all of the documents referred to
above which have been or may be incorporated in this Prospectus by reference,
other than exhibits to such documents which are not specifically incorporated by
reference into such documents. Requests for such copies should be directed to
Cheryl D. Hodges, Senior Vice President and Secretary, Omnicare, Inc., c/o
Omnicare Management Company, 2800 Chemed Center, 255 East Fifth Street,
Cincinnati, Ohio 45202, telephone number (513) 762-6666.

                                   THE COMPANY

         Omnicare is a leading independent provider of pharmacy services to
long-term care institutions such as nursing homes, retirement centers and other
institutional health care facilities. The Company purchases, repackages and
dispenses pharmaceuticals, both prescription and non-prescription, and provides
computerized medical recordkeeping and third-party billing for patients in such
facilities. The Company also provides consultant pharmacist services, including
evaluating monthly patient drug therapy, monitoring the control, distribution
and administration of drugs within the nursing facility and assisting in
compliance with state and federal regulations. In addition, the Company provides
ancillary services, such as infusion therapy, and distributes medical supplies
to its client nursing facilities. The Company currently provides these services
to approximately 421,000 residents in approximately 5,200 nursing homes and
other long-term care facilities in 36 states.

         The Company's executive offices are located at 50 East Rivercenter
Blvd. - Suite 1530, Covington, Kentucky 41011, and its telephone number is (606)
655-1180.

                                       4
<PAGE>   5
                              SELLING STOCKHOLDERS

         Set forth below for each of the Selling Stockholders, who acquired
Shares in connection with the acquisitions identified on the cover page of this
Prospectus, are the maximum number of Shares that may be sold by such Selling
Stockholder hereunder.

<TABLE>
<CAPTION>
SELLING STOCKHOLDER                                    NUMBER OF SHARES OWNED
- -------------------                                    ----------------------
<S>                                                    <C>    
Brookside Park Pharmacy, Inc.                                 182,535

Brookside Park Pharmacy of Texas, L.L.C.                      324,507

Brookside Park Pharmacy of Illinois, L.L.C.                   169,014
</TABLE>


                              PLAN OF DISTRIBUTION

         The Company is not aware of any plan of distribution with respect to
the Shares. Distribution of the Shares by the Selling Stockholders may be
effected from time to time in one or more transactions (which may involve block
transactions) (i) on the New York Stock Exchange, (ii) in the over-the-counter
market, (iii) in transactions otherwise than on such exchange or in the
over-the-counter market or (iv) in a combination of any such transactions. Such
transactions may be effected by the Selling Stockholders at market prices
prevailing at the time of sale, at prices related to such prevailing market
prices, at negotiated prices or at fixed prices. The Selling Stockholders may
effect such transactions by selling Shares to or through underwriters, brokers
or dealers, and such underwriters, brokers or dealers may receive compensation
in the form of discounts or commissions from the Selling Stockholders and may
receive commissions from the purchasers of Shares for whom they may act as
agent. Omnicare has agreed to indemnify the Selling Stockholders against certain
civil liabilities, including liabilities under the Securities Act.

                           DESCRIPTION OF COMMON STOCK

         The Common Stock has no preemptive rights and no redemption, sinking
fund or conversion provisions. All shares of Common Stock have one vote on any
matter submitted to the vote of stockholders. The Common Stock does not have
cumulative voting rights. Upon any liquidation of the Company, the holders of
Common Stock are entitled to receive, on a pro rata basis, all assets then
legally available for distribution after payment of debts and liabilities and
preferences on preferred stock, if any. Holders of Common Stock are entitled to
receive dividends when and as declared by the Board of Directors out of funds
legally available therefor (subject to the prior rights of preferred stock, if
any). All outstanding shares of Common Stock are fully paid and nonassessable.
The Board of Directors, without further action by the stockholders, is
authorized to issue preferred stock in one or more series and to designate as to

                                       5
<PAGE>   6
any such series the dividend rate, redemption prices, preferences on liquidation
or dissolution, sinking fund terms, conversion rights, voting rights and any
other preferences or special rights and qualifications.

         With certain exceptions, in the event a person owns 10% or more of the
Company's stock entitled to vote, the approval of holders of a majority of the
shares not so owned is required to authorize (1) any merger of the Company with
such person, (2) any sale, lease or other disposition of all or substantially
all of the Company's assets to such person or (3) certain issuances and
transfers of securities of the Company to such person. Directors may be removed
without cause only by the affirmative vote of the holders of two-thirds of the
Company's capital stock entitled to vote on the election of directors. The Board
of Directors of the Company, when evaluating any offer of another person to make
a tender or exchange offer, merge or purchase or otherwise acquire all or
substantially all of the assets of the Company, shall, in connection with the
exercise of its judgment in determining what is in the best interests of the
Company and its stockholders, give due consideration to all relevant factors,
including the social and economic effects on employees, customers, suppliers and
other constituents of Omnicare and on the communities in which Omnicare operates
or is located. The sections of the Company's Restated Certificate of
Incorporation described in this paragraph may not be altered, amended or
repealed without approval of the holders of two-thirds of the outstanding shares
of each class entitled to vote thereon as a class.

                                     EXPERTS

         The audited financial statements incorporated in this Prospectus by
reference to the Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 1996 (as amended on Form 10-K/A filed August 6, 1997) have been so
incorporated in reliance on the report of Price Waterhouse LLP to the extent and
for the periods appearing therein, given on the authority of said firm as
experts in auditing and accounting.

         The audited financial statements of American Medserve Corporation as 
of and for the year ended December 31, 1996 incorporated in this Prospectus by 
reference to the Company's Current Report on Form 8-K dated September 12, 1997 
(filed on September 19, 1997) have been so incorporated in reliance on the 
report of Ernst & Young LLP to the extent and for the periods appearing 
therein, given on the authority of said firm as experts in auditing and 
accounting. 

                                  LEGAL MATTERS

         The validity of the issuance of the Shares offered hereby by the
Selling Stockholders will be passed upon for the Company by Thompson Hine &
Flory LLP.

                                       6
<PAGE>   7
                                   PART II

                   INFORMATION NOT REQUIRED IN THE PROSPECTUS

ITEM 14.  OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION

         The following is an itemized statement of the expenses (all but the SEC
fees are estimates) in connection with the issuance of the Shares being
registered hereunder. All such expenses will be borne by the Company.

<TABLE>
<CAPTION>
<S>                                                                            <C>     
SEC Registration Fee.........................................................  $  6,044
Legal Fees and expenses......................................................  $ 10,000
Accounting fees and expenses.................................................  $  2,500
Miscellaneous................................................................  $  6,456
                                                                               --------
         Total...............................................................  $ 25,000
                                                                               =========
</TABLE>

ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS

         The Restated Certificate of Incorporation and Bylaws of Omnicare, and
separate Indemnification Agreements, provide for the indemnification of each
director and officer of Omnicare in connection with any claim, action, suit or
proceeding brought or threatened by reason of his or her position with Omnicare.
In addition, the General Corporation Law of the State of Delaware ("Delaware
Law") permits Omnicare to indemnify its directors, officers and others against
judgments, fines, amounts paid in settlement and attorneys' fees resulting from
various types of legal actions or proceedings if the actions of the party being
indemnified meet the standards of conduct specified in the Delaware Law.

         The Company's directors and officers are, in addition, insured against
loss arising from any claim against them or a wrongful act or omission with
certain exceptions and limitations.

ITEM 16. EXHIBITS.

         Each of the following Exhibits is filed herewith or incorporated by
reference in this Registration Statement.

<TABLE>
<CAPTION>
Exhibit
Number                                    Description of Exhibit
- ------                                    ----------------------
<S>      <C>
3(a)     Restated Certificate of Incorporation of the Company (incorporated by
         reference to Exhibit 3(a) to Registration Statement No. 33-59689).

3(b)     Certificate of Amendment of Restated Certificate of Incorporation of
         the Company (incorporated by reference to Exhibit 3(b) to Registration
         Statement No. 333-7695).

3(c)     By-laws of the Company, as amended (incorporated by reference to
         Exhibit 3 of the Company's 1994 Annual Report on Form 10-K).

5        Opinion of Thompson Hine & Flory LLP with respect to the legality of
         the securities being registered.*

23(a)    Consent of Price Waterhouse LLP.

23(b)    Consent of Ernst & Young LLP.

23(c)    Consent of Thompson Hine & Flory LLP (contained in Exhibit 5).*

24       Power of Attorney (included on signature page).

- -------
*  Filed previously
</TABLE>

                                       7
<PAGE>   8
ITEM 17. UNDERTAKINGS.

         The undersigned Registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933 (the "Act"), each
filing of the Registrant's annual report pursuant to Section 13(a) or Section
15(d) of the Securities Exchange Act of 1934 (the "Exchange Act") (and, where
applicable, each filing of an employee benefit plan's annual report pursuant to
Section 15(d) of the Exchange Act) that is incorporated by reference in the
Registration Statement shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.

         Insofar as indemnification for liabilities arising under the Act may be
permitted to directors, officers and controlling persons of the Registrant
pursuant to the foregoing provisions described under Item 15 above, or
otherwise, the Registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as
expressed in the Act and is, therefore, unenforceable. In the event that a claim
for indemnification against such liabilities (other than the payment by the
Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the Registrant will, unless in
the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the Act and will
be governed by the final adjudication of such issue.

         The undersigned registrant hereby undertakes:

                  (1) To file, during any period in which offers or sales are
         being made, a post-effective amendment to this registration statement:

                  (i) To include any prospectus required by Section 10(a)(3) of
         the Securities Act of 1933;

                  (ii) To reflect in the prospectus any facts or events arising
         after the effective date of the registration statement (or the most
         recent post-effective amendment thereof) which, individually or in the
         aggregate, represent a fundamental change in the information set forth
         in the registration statement. Notwithstanding the foregoing, any
         increase or decrease in volume of securities offered (if the total
         dollar value of securities offered would not exceed that which was
         registered) and any deviation from the low or high end of the estimated
         maximum offering range may be reflected in the form of prospectus filed
         with the Commission pursuant to Rule 424(b) if, in the aggregate, the
         changes in volume and price represent no more than a 20% change in the
         maximum aggregate offering price set forth in the "Calculation of
         Registration Fee" table in the effective registration statement; and

                  (iii) To include any material information with respect to the
         plan of distribution not previously disclosed in the registration
         statement or any material change to such information in the
         registration statement;

provided, however, that paragraphs (i) and (ii) above do not apply if the
information required to be included in a post-effective amendment by those
paragraphs is contained in periodic reports filed by the registrant pursuant to
section 13 or section 15(d) of the Securities Exchange Act of 1934 that are
incorporated by reference in the registration statement;

                  (2) That, for the purpose of determining any liability under
the Securities 

                                       8
<PAGE>   9
Act of 1933, each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof; and

                  (3) To remove from registration by means of a post-effective
amendment any of the securities being registered which remain unsold at the
termination of the offering.

         The undersigned registrant hereby undertakes that: (1) For purposes of
determining any liability under the Securities Act of 1933, the information
omitted from the form of prospectus filed as part of this registration statement
in reliance upon Rule 430A and contained in a form of prospectus filed by the
registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act
shall be deemed to be part of this registration statement as of the time it was
declared effective; and (2) For the purpose of determining any liability under
the Securities Act of 1933, each post-effective amendment that contains a form
of prospectus shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.

                                       9
<PAGE>   10
                                   SIGNATURES

         Pursuant to the requirements of the Securities Act of 1933, the
registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on a Form S-3 and has duly caused this
registration statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Cincinnati, State of Ohio on the 20th day of
November, 1997.

                                   OMNICARE, INC.


                                   By:   /s/ Joel F. Gemunder
                                       -----------------------------------
                                           Joel F. Gemunder, President
        
PRINCIPAL EXECUTIVE OFFICERS:

<TABLE>
<CAPTION>
<S>                                         <C>                                 <C>
                                            Chairman and
        *                                   Director                            November 20, 1997
- ------------------------------------
Edward L. Hutton

                                            President and
        *                                   Director                            November 20, 1997
- ------------------------------------
Joel  F. Gemunder


PRINCIPAL FINANCIAL AND ACCOUNTING
OFFICER:
                                            Senior Vice
                                            President and Chief
        *                                   Financial Officer                   November 20, 1997
- ------------------------------------
David W. Froesel, Jr.

DIRECTORS OF THE COMPANY:

        *                                                                       November 20, 1997
- ------------------------------------
Ronald K. Baur

        *                  
- ------------------------------------                                            November 20, 1997
Kenneth W. Chesterman
</TABLE>

                                       10
<PAGE>   11
<TABLE>
<CAPTION>
<S>                                                                             <C> 
- ------------------------------------                                            November 20, 1997
Charles H. Erhart, Jr.


               *                                                                November 20, 1997
- ------------------------------------
Mary Lou Fox  


                                                                                November 20, 1997
- ------------------------------------
Cheryl D. Hodges


               *                                                                November 20, 1997
- ------------------------------------
Thomas C. Hutton


               *                                                                November 20, 1997
- ------------------------------------
Patrick E. Keefe


               *                                                                November 20, 1997
- ------------------------------------
Sandra E. Laney


               *                                                                November 20, 1997
- ------------------------------------
Andrea R. Lindell


               *                                                                November 20, 1997
- ------------------------------------
Sheldon Margen


               *                                                                November 20, 1997
- ------------------------------------
Kevin J. McNamara


                                                                                November 20, 1997
- ------------------------------------
John M. Mount


               *                                                                November 20, 1997
- ------------------------------------
D. Walter Robbins, Jr.


/s/ Cheryl D. Hodges
- ------------------------------------
* By Cheryl D. Hodges, as attorney-in-fact
</TABLE>

                                       11
<PAGE>   12
                                INDEX TO EXHIBITS


<TABLE>
<CAPTION>
Exhibit
Number            Description
- ------            -----------
<S>               <C>
3(a)              Restated Certificate of
                  Incorporation of the Company
                  (incorporated by reference to
                  Exhibit 3(a) to Registration
                  Statement No. 33-59689).

3(b)              Certificate of Amendment of
                  Restated Certificate of
                  Incorporation of the Company
                  (incorporated by reference to
                  Exhibit 3(b) to Registration
                  Statement No. 333-7695).

3(c)              By-laws of the Company, as amended
                  (incorporated by reference
                  to Exhibit 3 of the Company's
                  1994 Annual Report on Form 10-K).

5                 Opinion of Thompson Hine &
                  Flory LLP with respect to
                  the legality of the
                  securities being registered.*

23(a)             Consent of Price Waterhouse LLP.

23(b)             Consent of Ernst & Young LLP.

23(c)             Consent of Thompson Hine &
                  Flory LLP (contained in
                  Exhibit 5).*

24                Power of Attorney (included on signature page).

- --------
* Filed previously
</TABLE>

                                       12

<PAGE>   1
                                                                   EXHIBIT 23(a)


                       Consent of Independent Accountants


         We hereby consent to the incorporation by reference in the Prospectus
constituting part of this Registration Statement on Form S-3 of our report dated
January 29, 1997 appearing on page 27 of Omnicare, Inc.'s Annual Report on Form
10-K/A for the year ended December 31, 1996. We also consent to the reference to
us under the heading "Experts" in such Prospectus.

                                      /s/Price Waterhouse LLP

Cincinnati, Ohio
November 20,1997

                                       13

<PAGE>   1
                                                                   EXHIBIT 23(b)


                        CONSENT OF INDEPENDENT AUDITORS


         We consent to the reference to our Firm under the caption ""Experts''
in the Registration Statement on Form S-3 and related Prospectus of Omnicare,
Inc. for the registration of 676,056 shares of its common stock and to the
incorporation by reference therein, of our report dated March 19, 1997 with
respect to the consolidated financial statements and schedule of American
Medserve Corporation included in its Form 10-K for the year ended December 31,
1996 filed with the Securities and Exchange Commission. 

                                      /s/Ernst & Young LLP

Chicago, Illinois
November 21, 1997


                                      14


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission